{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:32:42Z","timestamp":1791948762288,"version":"4.3.4"},"reference-count":50,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Emicizumab prophylaxis has been approved in Canada for the prevention or reduction of bleeding episodes in people with congenital hemophilia A (PwHA). Using routinely collected health data from the Canadian Bleeding Disorders Registry (CBDR), this observational cohort study aimed to evaluate the long-term safety and effectiveness of emicizumab in PwHA. Deidentified data from the CBDR were collected for PwHA who had received \u22651 dose of emicizumab from 2018 up to 31 December 2023. Intrapatient comparisons of annualized bleeding rates (ABRs) for all reported bleeds before and after emicizumab were performed using a negative binomial regression model. Overall, 710 PwHA received \u22651 emicizumab dose, and 539 (75.9%) had &amp;gt;1 year of emicizumab exposure. During the observational period, the safety profile was in keeping with previous reports; 34 adverse events were observed, including 2 thrombotic events (1 unlikely related to emicizumab; 1 probably related to previous use of eptacog alfa and\/or possibly related to previous emicizumab, and associated with a central venous access device). Over a median (first to third quartiles) follow-up time of 549 (374-690) days, 439 (61.8%) PwHA had no recorded bleeds. Mean ABR decreased from 1.00 (95% confidence interval [CI], 0.87-1.14) before emicizumab to 0.47 (95% CI, 0.40-0.55) after emicizumab (rate ratio, 0.47 [95% CI, 0.41-0.55]; P&amp;lt; .001). A notable decrease in bleeds and sustained bleed control were observed in this population for up to a 5-year follow-up period. Continued follow-up will allow for greater quantification of this impact over time, providing valuable information to health care practitioners and regulatory authorities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019430","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:54:57Z","timestamp":1784296497000},"page":"6862-6872","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-8766","authenticated-orcid":false,"given":"Alfonso","family":"Iorio","sequence":"first","affiliation":[{"name":"1Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0802-3616","authenticated-orcid":false,"given":"Federico","family":"Germini","sequence":"additional","affiliation":[{"name":"1Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"2IRCCS Humanitas Research Hospital, Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9302-0884","authenticated-orcid":false,"given":"Quazi","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"1Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0733-9616","authenticated-orcid":false,"given":"Arun","family":"Keepanasseril","sequence":"additional","affiliation":[{"name":"1Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Matino","sequence":"additional","affiliation":[{"name":"1Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7539-6490","authenticated-orcid":false,"given":"Emma","family":"Iserman","sequence":"additional","affiliation":[{"name":"1Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2032-8997","authenticated-orcid":false,"given":"Adrienne","family":"Lee","sequence":"additional","affiliation":[{"name":"3Department of Medicine, The University of British Columbia, Victoria, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7014-9677","authenticated-orcid":false,"given":"Letizia","family":"Polito","sequence":"additional","affiliation":[{"name":"4F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Moreno","sequence":"additional","affiliation":[{"name":"4F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0933-6446","authenticated-orcid":false,"given":"Michelle","family":"Santos","sequence":"additional","affiliation":[{"name":"5Hoffmann-La Roche Ltd, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7012-2420","authenticated-orcid":false,"given":"Man-Chiu","family":"Poon","sequence":"additional","affiliation":[{"name":"6Medicine, Pediatrics and Oncology, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"issue":"suppl 6","key":"2026101311212991800_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"8","key":"2026101311212991800_bib2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026101311212991800_bib3","unstructured":"World Federation of Hemophilia\n          . Annual Global Survey 2024. Accessed 3 July 2026. https:\/\/www1.wfh.org\/publications\/files\/pdf-2588.pdf."},{"issue":"4","key":"2026101311212991800_bib4","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3390\/jcm12041368","article-title":"Mild and moderate hemophilia A: neglected conditions, still with unmet needs","volume":"12","author":"Castaman","year":"2023","journal-title":"J Clin Med"},{"issue":"7","key":"2026101311212991800_bib5","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1055\/s-0033-1354422","article-title":"Arthropathy in patients with moderate hemophilia a: a systematic review of the literature","volume":"39","author":"Di Minno","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"2026101311212991800_bib6","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort","year":"2019","journal-title":"Blood Transfus"},{"issue":"20","key":"2026101311212991800_bib7","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2026101311212991800_bib8","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"2026101311212991800_bib9","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood.2022019465","article-title":"Immune tolerance induction in development","volume":"141","author":"Berntorp","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026101311212991800_bib10","doi-asserted-by":"crossref","first-page":"10078","DOI":"10.1038\/s41598-023-36891-x","article-title":"Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab","volume":"13","author":"Valls","year":"2023","journal-title":"Sci Rep"},{"issue":"9","key":"2026101311212991800_bib11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2026101311212991800_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/hae.13754","article-title":"From the voices of people with haemophilia A and their caregivers: challenges with current treatment, their impact on quality of life and desired improvements in future therapies","volume":"25","author":"Wiley","year":"2019","journal-title":"Haemophilia"},{"issue":"7","key":"2026101311212991800_bib13","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026101311212991800_bib14","unstructured":"F. Hoffmann-La Roche Ltd\n          . Emicizumab, summary of product characteristics. 2024. Accessed 3 July 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hemlibra-epar-product-information_en.pdf."},{"issue":"13","key":"2026101311212991800_bib15","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2026101311212991800_bib16","doi-asserted-by":"crossref","first-page":"E295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"24","key":"2026101311212991800_bib17","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2026101311212991800_bib18","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"2026101311212991800_bib19","doi-asserted-by":"crossref","first-page":"e12837","DOI":"10.1002\/rth2.12837","article-title":"Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY)","volume":"6","author":"Jim\u00e9nez-Yuste","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2026101311212991800_bib20","doi-asserted-by":"crossref","first-page":"e12670","DOI":"10.1002\/rth2.12670","article-title":"Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5)","volume":"6","author":"Yang","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"14","key":"2026101311212991800_bib21","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial","volume":"143","author":"Pipe","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026101311212991800_bib22","doi-asserted-by":"crossref","first-page":"E168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"N\u00e9grier","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"2026101311212991800_bib23","doi-asserted-by":"crossref","first-page":"102415","DOI":"10.1016\/j.rpth.2024.102415","article-title":"Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review","volume":"8","author":"Young","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 1","key":"2026101311212991800_bib24","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1182\/blood-2019-128083","article-title":"Patterns and predictors of emicizumab adherence in people with hemophilia","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2026101311212991800_bib25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/hae.14755","article-title":"Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy","volume":"29","author":"Oka","year":"2023","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"2026101311212991800_bib26","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood-2024-199645","article-title":"Real-world adherence and persistence to emicizumab using a national US claims database","volume":"144","author":"Shapiro","year":"2024","journal-title":"Blood"},{"key":"2026101311212991800_bib27","first-page":"98","article-title":"Emicizumab prophylaxis in people with haemophilia A: summary of 10 years of safety data on thromboembolic events and thrombotic microangiopathy","volume":"30","author":"Sarouei","year":"2024","journal-title":"Haemophilia"},{"key":"2026101311212991800_bib28","unstructured":"Genentech Inc\n          . HEMLIBRA (emicizumab-kxwh) injection for subcutaneous use, prescribing information. 2018. Accessed 3 July 2026. https:\/\/www.gene.com\/download\/pdf\/hemlibra_prescribing.pdf."},{"key":"2026101311212991800_bib30","unstructured":"Pharmaceutical and Medical Devices Agency\n          . Hemlibra prescribing information. 2018. Accessed 3 July 2026. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/6343451."},{"key":"2026101311212991800_bib31","author":"Roche Canada","year":"2019"},{"key":"2026101311212991800_bib32","unstructured":"F. Hoffmann-La Roche Ltd\n          . Hemlibra product monograph. 2018. Accessed 3 July 2026. https:\/\/assets.roche.com\/f\/173850\/x\/e0145f9e2a\/hemlibra_pm_e.pdf."},{"key":"2026101311212991800_bib33","unstructured":"Canadian Hemophilia Society\n          . Hemlibra Access. Access to Emicizumab Expanded. 2022. Accessed 3 July 2026. https:\/\/www.hemophilia.ca\/hemlibra-access\/."},{"key":"2026101311212991800_bib34","unstructured":"Canadian Hemophilia Society\n          . Access to Emicizumab Expanded. 2024. Accessed 3 July 2026. https:\/\/chscontact.ca\/access-to-emicizumab-expanded\/."},{"issue":"4","key":"2026101311212991800_bib35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/hae.14005","article-title":"Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures","volume":"26","author":"McCary","year":"2020","journal-title":"Haemophilia"},{"issue":"5","key":"2026101311212991800_bib36","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/hae.14372","article-title":"Adoption of emicizumab (Hemlibra) for hemophilia A in Europe: data from the 2020 European Association for Haemophilia and Allied Disorders survey","volume":"27","author":"Krumb","year":"2021","journal-title":"Haemophilia"},{"issue":"3","key":"2026101311212991800_bib37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.14318","article-title":"Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring","volume":"27","author":"Barg","year":"2021","journal-title":"Haemophilia"},{"issue":"suppl 2","key":"2026101311212991800_bib38","article-title":"Emicizumab treatment in pediatric haemophilia A patients: &gt;1 year safety based on real-world data from the PedNet cohorts","volume":"5","author":"Kenet","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 1","key":"2026101311212991800_bib39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2022-157528","article-title":"Real-world safety of emicizumab: interim analysis of the European haemophilia safety surveillance (EUHASS) database","volume":"140","author":"Nissen","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2026101311212991800_bib40","article-title":"Reflections on the Canadian Bleeding Disorders Registry: lessons learned and future perspectives","volume":"2","author":"Iorio","year":"2022","journal-title":"Can J Med Technol"},{"issue":"16","key":"2026101311212991800_bib41","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026101311212991800_bib42","doi-asserted-by":"crossref","first-page":"103164","DOI":"10.1016\/j.rpth.2025.103164","article-title":"Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors\u2019 Organisation","volume":"9","author":"Wall","year":"2025","journal-title":"Res Prac Thromb Haemostas"},{"key":"2026101311212991800_bib43","volume-title":"Poster presented at: ISTH","author":"Mancuso","year":"9-13  2022"},{"issue":"7","key":"2026101311212991800_bib44","doi-asserted-by":"crossref","first-page":"103215","DOI":"10.1016\/j.rpth.2025.103215","article-title":"Emicizumab prophylaxis in current haemophilia A care in the Czech Republic-data from the Czech National Haemophilia Programme Registry","volume":"9","author":"Z\u00e1potock\u00e1","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2026101311212991800_bib45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/hae.70151","article-title":"Safety and effectiveness of emicizumab in people with haemophilia A enrolled in the ATHN 7 Haemophilia Natural History Study","volume":"32","author":"Buckner","year":"2026","journal-title":"Haemophilia"},{"key":"2026101311212991800_bib46","unstructured":"National Bleeding Disorders Foundation\n          . MASAC Document 268 - Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra) for Hemophilia A with and without Inhibitors. 2022. Accessed 3 July 2026. https:\/\/www.hemophilia.org\/healthcare-professionals\/guidelines-on-care\/masac-documents\/masac-document-268-recommendation-on-the-use-and-management-of-emicizumab-kxwh-hemlibrar-for-hemophilia-a-with-and-without-inhibitors."},{"issue":"8","key":"2026101311212991800_bib47","doi-asserted-by":"crossref","first-page":"102239","DOI":"10.1016\/j.rpth.2023.102239","article-title":"Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis","volume":"7","author":"Hermans","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 1","key":"2026101311212991800_bib48","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2022-157754","article-title":"Emicizumab and females with hemophilia A: case series from ATHN 7","volume":"140","author":"Recht","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026101311212991800_bib49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/hae.14212","article-title":"Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: real-world experience from a large comprehensive treatment centre in the US","volume":"27","author":"Lewandowska","year":"2021","journal-title":"Haemophilia"},{"issue":"2","key":"2026101311212991800_bib50","doi-asserted-by":"crossref","first-page":"100077","DOI":"10.1016\/j.rpth.2023.100077","article-title":"Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis","volume":"7","author":"Pipe","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2026101311212991800_bib51","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13023-019-1088-3","article-title":"The DM-scope registry: a rare disease innovative framework bridging the gap between research and medical care","volume":"14","author":"De Antonio","year":"2019","journal-title":"Orphanet J Rare Dis"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6862\/2594631\/blooda_adv-2025-019430-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6862\/2594631\/blooda_adv-2025-019430-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:21:37Z","timestamp":1791904897000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6862\/569751\/Long-term-experience-with-emicizumab-in-people"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":50,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019430","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,10,13]]}}}